Clinical trials: Metastatic Liver Disease
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT05791448
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
Alpha-1-antitrypsin Deficiency, Emphysema
Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency
Emphysema linked to alpha-1-antitrypsin deficiency (DAAT): towards a better prediction of risks Emphysema caused by alpha-1-antitrypsin deficiency (DAAT) is a rare genetic disorder that can lead to serious complications, such as…
- Conditions
- Alpha-1-antitrypsin Deficiency, Emphysema, Artificial Intelligence (AI), Predictive Learning Models
- Trial name
- FLARE (NCT07715617)
- Where
- 4 sites in France
- Volunteers
- 230 people
- Sponsor
- University Hospital, Bordeaux
Metastatic Colo-rectal Cancer
LOTCOL Study: Local Treatment of Colo-rectal Liver Met
In this study the investigators will include colo-rectal cancer (CRC) patients starting last line of standard palliative chemotherapy.
- Trial name
- LOTCOL (NCT01867918)
- Testing
- Radiofrequency ablation, microwave, radiation therapy, Standard Chemotherapy
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- Oslo University Hospital
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma, Liver Cancer
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
- Trial name
- NCT04502082
- Testing
- ET140203 autologous T cell product
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eureka Therapeutics Inc.
Hepatocellular Carcinoma (HCC)
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
- Trial name
- NCT00355238
- Testing
- brivanib (active)
- Where
- 37 sites in United States, France and 6 more
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
Hepatic Cirrhosis, Portal Hypertension
The Treatment of Hepatocirrhosis and Portal Hypertension
This study compare the efficiency of partial splenic embolization +endoscopical therapy with endoscopical therapy alone in gastroesophageal variceal haemorrhage accompanied with splenomegaly or hypersplenism of hepatocirrhosis…
- Trial name
- NCT02778425
- Testing
- Endoscopic therapy+ beta blockers, Endoscopic therapy+ PSE+beta blockers, beta blockers
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Yanjing Gao
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
In this trial chemotherapy regimen FOLFOX with intrahepatic administration of oxaliplatin is combined with immunotherapy (nivolumab and ipilimumab) for the group of patients with multiple liver metastasis from colorectal cancer.
- Trial name
- IMMUNOX (NCT04430985)
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- Denmark
- Sponsor
- Dorte Nielsen
Radiotherapy, Immunotherapy
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
- Trial name
- NCT03589339
- Testing
- NBTXR3, SABR, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 145 people
- Sponsor
- Nanobiotix
Hepatocellular Carcinoma
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular carcinoma.
- Trial name
- NCT00142467
- Testing
- Gemcitabine, Oxaliplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation
Colorectal Cancer
A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy
Objective: To assess the effect of bevacizumab on tumor vessels, and the reversibility of the effect, using contrast-enhanced ultrasonography (CEUS) and histology in patients with metastatic liver tumors derived from colorectal…
- Trial name
- NCT01591109
- Volunteers
- 20 people
- Sponsor
- NHO - Matsumoto Medical Center
Pancreatic Cancer, Liver Metastasis
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis.
- Trial name
- NCT04420130
- Testing
- Camrelizumab, Chemotherapy, Ablation
- Sponsor
- Yanqiao Zhang
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Study of GNS561 in Patients With Liver Cancer
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
- Trial name
- NCT03316222
- Testing
- GNS561
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Genoscience Pharma
Liver Metastasis, Gastric Cancer
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
Objectives: The purpose of this study is to evaluate the safety and efficacy of PIK-HER2 cells in the treatment of advanced Her2 high expressed gastric cancer with liver metastasis patients.
- Trial name
- NCT02632201
- Testing
- PIK-HER2, DC-PMAT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Military Medical University
Colorectal Cancer Metastatic, Colon Cancer
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy…
- Conditions
- Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer
- Trial name
- iRE-C (NCT04108481)
- Testing
- Durvalumab, Yttrium-90 RadioEmbolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Iowa
Colorectal Cancer
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
- Trial name
- PICASSO (NCT01343901)
- Testing
- Bevacizumab
- Where
- 126 sites in France
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.